BiotechTube

Trivalent Influenza Vaccine

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Influenza

Conditions

Influenza, Healthy

Trial Timeline

May 1, 2013 → Dec 1, 2013

NCT ID
NCT01859143

About Trivalent Influenza Vaccine

Trivalent Influenza Vaccine is a approved stage product being developed by AstraZeneca for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT01859143. Target conditions include Influenza, Healthy.

What happened to similar drugs?

20 of 20 similar drugs in Influenza were approved

Approved (20) Terminated (2) Active (0)
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)AstraZenecaApproved
✅Trivalent Influenza Virus VaccineAstraZenecaApproved
✅Vaxelis + PedvaxHIBMerckApproved
✅Fluvirin(TIVf) + Agriflu (TIV)NovartisApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02473510ApprovedCompleted
NCT01859143ApprovedCompleted

Competing Products

20 competing products in Influenza

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 2
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1083.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1083ModernaPhase 3
0
mRNA-1073ModernaPhase 2
0
VAL-506440ModernaPhase 1
0
mRNA-1083ModernaPhase 3
0
mRNA-1083ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
VAL-339851ModernaPhase 1
0
mRNA-1018-H5ModernaPhase 3
0
mRNA-1653ModernaPhase 1
0
mRNA-1030ModernaPhase 2
0
mRNA-1018 for H5N8ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0